A study presented at the American Society of Nephrology found that the benefits of the drug empagliflozin in treating chronic kidney disease (CKD) begin to diminish within about a year after treatment is stopped. The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of kidney disease or progression by 28% compared to a placebo over 2 years. However, the benefits decrease after discontinuation of treatment. Overall, the study suggests that ongoing treatment with empagliflozin is needed to maximize the kidney and cardiovascular benefits for patients with CKD. The findings have important implications for long-term treatment of CKD patients.
Source link
Empagliflozin Effects Subside With Discontinuation
